Obesity and Overweight in American Indian and Alaska Native Children, 2006-2015

Ann Bullock1, Karen Sheff1, Kelly Moore1

  • 1Ann Bullock and Karen Sheff are with the Division of Diabetes Treatment and Prevention, Office of Clinical and Preventive Services, Indian Health Service, Rockville, MD. Kelly Moore and Spero Manson are with the Centers for American Indian and Alaska Native Health, Colorado School of Public Health, University of Colorado Denver, Aurora.

Insights

Obesity and overweight prevalence in American Indian and Alaska Native (AI/AN) children remains high, with 29.7% obesity in 2015. Rates may have stabilized but exceed those of US children overall.

Area of Science:

  • Pediatric Health
  • Public Health
  • Epidemiology

Background:

  • Childhood obesity is a significant public health concern.
  • American Indian and Alaska Native (AI/AN) children face unique health disparities.
  • Understanding prevalence is crucial for targeted interventions.

Purpose of the Study:

  • To estimate obesity and overweight prevalence in AI/AN children.
  • Analyze prevalence across genders, ages, and geographic regions.
  • Compare AI/AN children's prevalence to the general US population.

Main Methods:

  • Utilized data from the Indian Health Service National Data Warehouse (2006-2015).
  • Included over 184,000 AI/AN children aged 2-19 years.
  • Calculated BMI percentiles using CDC 2000 growth charts.

Main Results:

  • In 2015, overweight prevalence was 18.5% and obesity was 29.7% in AI/AN children.
  • Boys exhibited higher obesity rates (31.5%) than girls (27.9%).
  • Adolescents (12-19 years) showed higher overweight/obesity prevalence than younger children.

Conclusions:

  • Overweight and obesity prevalence in AI/AN children may have stabilized.
  • Prevalence remains significantly higher compared to US children overall.
  • Continued monitoring and culturally relevant interventions are warranted.
Abstract

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
314
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
322
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
247
Binge Eating Disorders01:23

Binge Eating Disorders

Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
563
Prevalence and Incidence01:08

Prevalence and Incidence

In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
2.1K